This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Congenital Stenosis of Vena Cava
1. History
Congenital stenosis of the vena cava is a very rare lesion among congenital cardiovascular malformations and was first described in autopsy reports in the early 20th century. Clinically, because the clinical significance and treatment approach of superior vena cava (SVC) and inferior vena cava (IVC) stenosis differ, they have historically tended to be described separately.
Superior vena cava stenosis arises from both congenital and acquired causes; congenital cases are known to involve membranous stenosis due to abnormal vascular development or stenosis due to extrinsic compression. Inferior vena cava stenosis is one of the causes of Budd-Chiari syndrome, and membranous obstruction/stenosis at the hepatic vein inflow or within the inferior vena cava is reported relatively frequently in Asia (Korea, Japan, China, India).
The history of treatment changed greatly with the development of percutaneous balloon angioplasty and stent placement since the 1980s. Previously, surgical bypass was the only treatment option, but interventional procedures are now established as first-line treatment. In Korea, experience has accumulated with interventional treatment of Budd-Chiari syndrome, including membranous obstruction of the inferior vena cava.
2. Causes
Congenital stenosis of the vena cava can arise from the following causes:
Congenital stenosis of the superior vena cava (SVC):
Membranous stenosis: a fibrous membrane forms at the superior vena cava–right atrium junction, causing stenosis.
Abnormal vascular development: the superior vena cava may be hypoplastic or stenotic due to abnormal development of the embryonic anterior cardinal vein.
Extrinsic compression: compression by mediastinal tumors such as congenital bronchogenic cysts and teratomas (must be distinguished from 'congenital stenosis' in the strict sense).
Congenital stenosis of the inferior vena cava (IVC):
Membranous stenosis/obstruction (membranous obstruction of IVC, MOVC): a fibrous membrane forms at the inferior vena cava–right atrium junction or in the intrahepatic inferior vena cava, causing stenosis/obstruction. It is a cause of Budd-Chiari syndrome.
Abnormal vascular development: congenital hypoplasia or segmental absence of the inferior vena cava.
Left-sided IVC: a rare variant. Mostly asymptomatic, but there may be a risk of thromboembolism.
It may also occur as part of congenital malformations: inferior vena cava abnormalities may accompany asplenia/polysplenia, situs ambiguus, complex cardiac malformations, and others.
3. Genetics
Specific genetic causes of congenital stenosis of the vena cava have not yet been sufficiently elucidated.
Heterotaxy syndrome:
Mutations in genes such as CFC1 (CRYPTIC), ZIC3, ACVR2B, and NODAL are involved in determining visceral left-right asymmetry, and inferior vena cava abnormalities (interrupted inferior vena cava, azygos continuation) may accompany this process.
X-linked heterotaxy asplenia syndrome is caused by ZIC3 mutations.
Membranous obstruction of the inferior vena cava (MOVC):
It is presumed to result from embryonic thrombus formation or abnormal vascular development rather than genetic predisposition, and there are reports that coagulation factor abnormalities (inherited thrombophilia such as factor V Leiden) are present in some cases.
Associated congenital heart malformations:
When inferior vena cava abnormalities appear as part of complex congenital heart malformations (single ventricle, heart malformations associated with asplenia/polysplenia syndrome, etc.), the genetic cause of that malformation should be investigated.
For comprehensive genetic evaluation, chromosomal microarray and cardiovascular gene panel testing may be considered.
4. General epidemiology
Congenital stenosis of the vena cava is a very rare malformation, and accurate incidence data are lacking.
Congenital SVC stenosis: extremely rare, at the level of case reports, with no incidence statistics.
IVC membranous obstruction (MOVC, a cause of Budd-Chiari syndrome):
It is reported at a higher frequency in Asia (Korea, Japan, China, India) than in Western countries.
A considerable proportion of Budd-Chiari syndrome patients in Korea are due to IVC membranous obstruction or stenosis.
The age of onset varies, but it is often diagnosed in adults, and some cases are detected in childhood.
IVC abnormalities associated with complex heart malformations:
IVC interruption is common in asplenia/polysplenia syndrome, and blood flow is diverted to the superior vena cava through azygos vein continuation. This is a lesion different from stenosis in the strict sense, but it is described together in the context of IVC flow abnormalities.
It is eligible for Special Copayment Reduction V150 in Korea, and appropriate specialized treatment is needed after diagnosis.
5. Pathophysiology
The pathophysiology of vena cava stenosis differs according to the site and degree of stenosis.
SVC stenosis:
When superior vena cava venous return is restricted, venous hypertension of the head, neck, and upper extremities develops.
Findings of 'superior vena cava syndrome (SVC syndrome)' appear, such as edema of the head, face, and upper extremities, jugular venous distension, headache, and visual disturbance.
Congenital lesions often remain asymptomatic into adulthood and are discovered incidentally or during testing for other conditions. In particular, IVC membranous obstruction often presents in middle age as Budd-Chiari syndrome.
7. Signs
Physical examination findings:
Signs of SVC stenosis:
Edema of the head, face, and upper extremities (edema of the face, neck, and arms more prominent than of the lower body)
Jugular venous distension: in both the supine and upright positions
Dilated veins of the upper extremities and chest wall: development of collateral vessels
Facial flushing and conjunctival injection
Pemberton sign: worsening of head and face edema and cyanosis when both arms are raised above the head (increased SVC compression)
Abdominal wall varices (caput medusae): radial venous dilation around the umbilicus
Jaundice (when liver function is reduced)
Splenomegaly (with portal hypertension)
Echocardiography/vascular ultrasound can confirm stenosis and flow abnormalities at the affected site.
8. Screening
Strategies for screening and early detection of congenital stenosis of the vena cava:
Screening for IVC stenosis/MOVC:
Abdominal ultrasound + Doppler: first-line evaluation of hepatomegaly, ascites, hepatic venous flow abnormalities, and IVC stenosis. IVC flow must be evaluated in patients with abnormal liver function.
Liver function tests (AST, ALT, bilirubin, albumin, PT/INR): assessment of the degree of reduced liver function.
In patients with ascites of unknown origin, hepatic vein Doppler and IVC ultrasound should be performed to differentiate Budd-Chiari syndrome.
Screening for SVC stenosis:
In patients with unexplained edema of the head, face, or upper extremities, SVC stenosis is excluded with chest CT or vascular ultrasound.
IVC abnormalities associated with heart malformations:
In patients with complex congenital heart malformations (especially suspected asplenia/polysplenia syndrome), abnormal IVC connections are evaluated with echocardiography and thoracoabdominal CT/MRI.
Family history screening: family testing is considered when a specific genetic cause is identified.
9. Diagnosis
Confirmation of vena cava stenosis and pretreatment evaluation:
CT angiography (CTA):
Precisely evaluates the site, degree, and extent of stenosis. Collateral vessel development, presence of thrombus, and associated malformations are also confirmed.
In IVC stenosis, overall evaluation of the hepatic vein inflow, intrahepatic IVC, and lower IVC is required.
MRI/MR angiography (MRA):
Useful in children and adolescents because the site of stenosis and blood flow can be evaluated without radiation exposure.
Also advantageous for evaluating the liver parenchyma (degree of fibrosis, cirrhosis).
Venography:
Can be performed simultaneously with interventional procedures (balloon dilation, stenting), allowing diagnosis and treatment to be combined.
In IVC membranous obstruction, the exact location of the membrane and the pressure gradient are measured.
Liver biopsy: used to assess the degree of liver fibrosis when reduced liver function or cirrhosis is suspected.
Blood tests: coagulation abnormalities (thrombophilia testing: factor V Leiden, PT20210A, protein C/S, antithrombin III, etc.) are evaluated to search for the cause of thrombosis.
10. Treatment
Treatment of vena cava stenosis is determined by the site and degree of stenosis and the clinical symptoms.
Treatment of IVC membranous obstruction (MOVC):
Percutaneous transluminal balloon angioplasty (PTA): first-line treatment. The site of membranous obstruction is dilated with a balloon. High success rate, and the procedure can be repeated.
Stent placement: when restenosis recurs after PTA or the initial dilation is insufficient, a stent is placed to maintain long-term patency.
Anticoagulation therapy: when thrombosis is present, heparin or LMWH followed by maintenance with warfarin or a DOAC.
Thrombolysis: local thrombolysis may be performed when there is acute thrombosis.
Surgical bypass: when percutaneous intervention fails or is anatomically difficult. An IVC–right atrium bypass or hepatic vein–right atrium anastomosis is performed.
Treatment of SVC stenosis:
Varies by cause. Membranous stenosis: PTA + stent. Removal of the cause of extrinsic compression.
Anticoagulation or thrombolysis when accompanied by thrombosis.
Liver transplantation: for end-stage liver failure or development of hepatocellular carcinoma.
11. Prognosis
The prognosis of vena cava stenosis differs according to the treatment method and the degree of liver function damage.
Prognosis after treatment of IVC membranous obstruction (MOVC):
PTA alone: the restenosis rate is high (~30–50% within 1–3 years), so repeat procedures are often needed.
After stent placement: improved long-term patency. A 5-year patency rate of ~70–90% is reported.
With successful intervention, reduction of ascites, recovery of liver function, and improved quality of life are expected.
Prognosis related to liver function:
If cirrhosis has progressed, recovery of liver function is limited even after intervention.
The risk of hepatocellular carcinoma (HCC) is significantly increased compared with the general population (annual incidence ~2–4%). Regular liver ultrasound and AFP monitoring are required.
Prognosis of SVC stenosis:
With successful intervention, edema of the head, face, and upper extremities and SVC syndrome symptoms improve.
Long-term patency rates vary depending on restenosis.
IVC abnormalities associated with complex heart malformations:
Determined by the prognosis of the underlying heart malformation; after the Fontan operation, it may progress to Fontan-associated liver disease (FALD).
12. Prevention
Prevention of congenital stenosis of the vena cava focuses on preventing thrombotic complications and early diagnosis.
Thrombophilia screening and prevention:
In patients with IVC membranous obstruction, inherited thrombophilia (factor V Leiden, prothrombin mutation, protein C/S deficiency, antithrombin III deficiency, etc.) is screened to evaluate the need for anticoagulation therapy.
If thrombophilia is confirmed, long-term oral anticoagulation is considered.
Regular follow-up:
After treatment of IVC stenosis, restenosis is monitored with vascular ultrasound and CT every 6–12 months.
Liver function tests and liver ultrasound are performed regularly for early detection of hepatocellular carcinoma.
Anticoagulation therapy is continued when there are risk factors for thromboembolism.
IVC abnormalities associated with complex heart malformations:
In patients after the Fontan operation, regular liver function tests and liver ultrasound are performed for early detection of FALD.
If necessary, the degree of fibrosis is assessed by liver biopsy.
Prenatal diagnosis: in fetuses with suspected asplenia/polysplenia syndrome, IVC abnormalities are evaluated with fetal echocardiography to prepare postnatal measures.
13. References
Okuda H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22(1):1-9. PMID:7890710
Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver Dis. 2008;28(3):259-269. PMID:18814077
Han G, et al. Budd-Chiari syndrome: treatment outcome with long-term follow-up. J Vasc Interv Radiol. 2012;23(9):1166-1175. PMID:22921342
Zhang CQ, et al. Treatment of Budd-Chiari syndrome: analysis of the benefit and defects of management strategies. J Gastroenterol Hepatol. 2004;19(12):1348-1354. PMID:15610311
Darwish Murad S, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167-175. PMID:19414839
Seijo S, et al. The role of heritable thrombophilic disorders in the etiology of Budd-Chiari syndrome. Hepatology. 2015;61(5):1655-1662. PMID:25620470
Kim TK, et al. Membranous obstruction of the inferior vena cava in Korea. Cardiovasc Intervent Radiol. 1998;21(1):29-35. PMID:9449527
Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;50(1):195-203. PMID:19014844
Smalberg JH, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2012;120(25):4921-4928. PMID:23043069
Garcia-Pagan JC, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors. J Hepatol. 2008;48(5):812-820. PMID:18331772